Zenas BioPharma, Inc.
ZBIO
$7.54
-$0.26-3.33%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 46.61% | -0.82% | |||
| Gross Profit | -31.69% | 0.82% | |||
| SG&A Expenses | 53.82% | 26.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.92% | 3.23% | |||
| Operating Income | -35.72% | -3.23% | |||
| Income Before Tax | -35.15% | -1.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -36.26% | -1.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -36.26% | -1.66% | |||
| EBIT | -35.72% | -3.23% | |||
| EBITDA | -35.76% | -3.23% | |||
| EPS Basic | 74.99% | 79.30% | |||
| Normalized Basic EPS | 75.59% | 79.30% | |||
| EPS Diluted | 75.01% | 79.28% | |||
| Normalized Diluted EPS | 75.59% | 79.30% | |||
| Average Basic Shares Outstanding | 444.73% | 391.14% | |||
| Average Diluted Shares Outstanding | 444.73% | 391.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
